BG-C137
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BG-C137, covering 2026-04-22 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors [Phase 1]